How To Build and Interpret a Nomogram for Cancer PrognosisAlexia Iasonos, Katherine S. Panageas, Deborah Schrag et al.|Journal of Clinical Oncology|2008Cited by 3.4k
Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer CenterTroy Z. Horvat, Paul B. Chapman, Kaitlin M. Woo et al.|Journal of Clinical Oncology|2015Cited by 1.1k
Phase III Multicenter Randomized Trial of the Dartmouth Regimen Versus Dacarbazine in Patients With Metastatic MelanomaPaul B. Chapman, John M. Kirkwood, Lawrence H. Einhorn et al.|Journal of Clinical Oncology|1999Cited by 763
Primary Central Nervous System Lymphoma: The Memorial Sloan-Kettering Cancer Center Prognostic ModelLauren E. Abrey, Lisa M. DeAngelis, Leah Ben‐Porat et al.|Journal of Clinical Oncology|2006Cited by 620
Effect of Selumetinib vs Chemotherapy on Progression-Free Survival in Uveal MelanomaRichard D. Carvajal, Gary K. Schwartz, Jeffrey A. Sosman et al.|JAMA|2014Cited by 429